Rationale

Larynx Preservation represents an important option for patients affected by Locally Advanced (LA) Laryngo-Hypopharyngeal Squamous Cell Carcinoma (LHSCC), given the chance to provide a curative treatment without affecting the ability to speak. However, to date the indications for the available strategies of Larynx Preservation – i.e., surgical preservation, induction chemotherapy, and concomitant chemoradiation treatment – are still debated. International Guidelines do not provide meticulous indications, instead recommending a case-by-case discussion also keeping into consideration the expertise of each Multidisciplinary Tumour Board.

The purpose of this Consensus Project is to dissect the topics with scanty literature, summarise the current evidence, point out the most debated questions, enlighten the fields needing further research and provide expert opinions on topics with inadequate clinical evidence.

Subscriptions

EARLY REGISTRATION: until December 31st 2023
REGULAR REGISTRATION: from January 1st 2024

Subscription at https://consensuslarynx.studioprogress.it/registration-form/

At the last ESMO Congress 2023 in Madrid, the GONO Foundation research group presented results from the latest translational analysis of the AtezoTRIBE trial, which has recently demonstrated that adding atezolizumab to first-line FOLFOXIRI/bevacizumab prolongs progression-free survival in metastatic colorectal cancer (mCRC) patients. Thanks to an international collaboration with Lunit inc, based in Korea, an artificial intelligence-powered whole-slide images (WSI) analyzer – LunitIO – was applied in order to analyze tumour infiltrating lymphocytes (TILs) in hematoxylin & eosin-stained WSI of tumour specimens collected at baseline from patients enrolled in the AtezoTRIBE study cohort. Lunit Scope IO identifies three immune-phenotypes, defined as: inflamed, characterized by TILs in tumor epithelium and stroma; excluded, with TILs-enriched stroma; desert, lacking in TILs. Contextually, inflamed score was calculated as the proportion of grids classified as inflamed within a whole slide image. Of 154 cases analyzed, 56% were immune-desert and 44% were immune-excluded, while no immune-inflamed cases were detected. Both immune phenotypes and inflamed score were correlated with well-known immune-related biomarkers (e.g. Immunoscore IC, Immunoscore, TMB, MMR status and TILs’ density by optical microscope), although no prognostic nor predictive roles were observed. Nevertheless, both parameters provide additional characterization of the tumor microenvironment in mCRC. Further development of Lunit Scope IO tools is currently ongoing with the aim to identify novel biomarkers of tumour immunogenicity, potentially predictive of benefit from the addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab.

Presentation of the GONO Infinity project at the congress.

INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).

Filippo Pietrantonio, Alessandra Raimondi, Sara Lonardi, Sabina Murgioni, Giovanni Gerardo Cardellino, Stefano Tamberi, Antonia Strippoli, Federica Palermo, Michele Prisciandaro, Giovanni Randon, Francesca Corti, Francesca Bergamo, Floriana Nappo, Alberto Giovanni Leone, Giuseppe Leoncini, Giovanna Sabella, Kristiyana Kaneva, Carlo Sposito, Maria Di Bartolomeo, Vincenzo Mazzaferro.

DOI: 10.1200/JCO.2023.41.4_suppl.358 Journal of Clinical Oncology 41, no. 4_suppl (February 01, 2023) 358-358.

– https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.4_suppl.358?af=R

Trop2 and Nectin4 immunohistochemical expression in metastatic colorectal cancer: An exploratory analysis of the TRIBE2 study

https://www.annalsofoncology.org/article/S0923-7534(22)02330-4/fulltext

An immune-related gene expression profile to predict the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the phase II randomized AtezoTRIBE study.

https://www.annalsofoncology.org/article/S0923-7534(22)01124-3/fulltext

Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO.

https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.17_suppl.LBA3505

Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC)

https://www.annalsofoncology.org/article/S0923-7534(21)03227-0/fulltext

The role of PP2A variants to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.

https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.3581